Clinical impact of down-regulated plasma miR-92a levels in non-hodgkin's lymphoma

血浆 miR-92a 水平下调对非霍奇金淋巴瘤的临床影响

• 批准号: 23701088
• 负责人: YOSHIZAWA Sei-ichiro
• 金额: $ 2.25万
• 依托单位: Tokyo Medical University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2013
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23701088/
• 关键词: 非ホジキンリンパ腫; 血清miRNA; miR-92a; 診断マーカー

To evaluate the clinical relevance of the miR-92a in plasma obtained from non-Hodgkin's lymphoma patients, because miR-92 miRNA plays a crucial role in lymphogenesis, as well as tumorigenesis in lymphoid tissue. We evaluated plasma miR-92a value; MicroRNA Assays with modifications with non-Hodgkin's lymphoma and compared results with healthy subjects. Plasma miR-92a values in non-Hodgkin's lymphoma were extremely low, compared to healthy subjects. At the time of diagnosis The down-regulated plasma miR-92a increased in the complete response phase, reaching normal control levels, and again becoming down-regulated in the relapse phase. In non-Hodgkin's lymphoma patients, while a decreased level of plasma miR-92a was evident, indicating that the discrepancy lymph circulating miR-92a might be an important clinical issue. The plasma miR-92a value could be a novel biomarker for monitoring lymphoma patients, especially in those with indolent lymphoma.

评估从非霍奇金淋巴瘤患者获得的血浆中的miR-92 a的临床相关性，因为miR-92 miRNA在淋巴发生中以及淋巴组织中的肿瘤发生中起关键作用。我们评估了血浆miR-92 a值;非霍奇金淋巴瘤修饰的MicroRNA测定，并与健康受试者的结果进行了比较。与健康受试者相比，非霍奇金淋巴瘤患者的血浆miR-92 a值极低。在诊断时，下调的血浆miR-92 a在完全反应期增加，达到正常对照水平，并在复发期再次下调。在非霍奇金淋巴瘤患者中，血浆miR-92 a水平明显降低，表明淋巴循环miR-92 a的差异可能是一个重要的临床问题。血浆miR-92 a值可能是监测淋巴瘤患者，特别是惰性淋巴瘤患者的一种新的生物标志物。

项目成果

Lower plasma miR-92a levels in newly diagnosed symptomatic multiple myeloma patients with poor-risk cytogenetics

新诊断的有症状且细胞遗传学风险较低的多发性骨髓瘤患者血浆 miR-92a 水平较低

• 发表时间: 2013
• 作者: Ohyashiki K;Umezu T;Yoshizawa S;Ito Y;Ohyashiki M;Kawashima H;Tanaka M;Kuroda M;Ohyashiki JH;Yoshizawa S;Yoshizawa S;Yoshizawa S
• 通讯作者: Yoshizawa S

Lower plasma miR-92a levels predict shorter progression-free survival in newly diagnosed symptomatic multiple myeloma patients.

较低的血浆 miR-92a 水平预示新诊断的有症状多发性骨髓瘤患者的无进展生存期较短。

• 发表时间: 2013
• 作者: Ohyashiki K;Umezu T;Yoshizawa S;Ito Y;Ohyashiki M;Kawashima H;Tanaka M;Kuroda M;Ohyashiki JH;Yoshizawa S;Yoshizawa S;Yoshizawa S;Yoshizawa S;Yoshizawa S;Yoshizawa S
• 通讯作者: Yoshizawa S

多発性骨髄腫における血清miR-92aの臨床的意義

血清miR-92a在多发性骨髓瘤中的临床意义

• 发表时间: 2011
• 作者: 吉澤成一郎;梅津知宏;藤本博昭;後藤守孝;木村之彦;大屋敷一馬;大屋敷純子
• 通讯作者: 大屋敷純子

Feasibility of plasma miR-92a as a prognostic marker in newly diagnosed multiple myeloma patients

血浆miR-92a作为新诊断多发性骨髓瘤患者预后标志物的可行性

• 发表时间: 2013
• 作者: Ohyashiki K;Umezu T;Yoshizawa S;Ito Y;Ohyashiki M;Kawashima H;Tanaka M;Kuroda M;Ohyashiki JH;Yoshizawa S;Yoshizawa S
• 通讯作者: Yoshizawa S

Plasma Mir-92a Levels in Multiple Myeloma Correlate with T-cell-Derived Mir-92a and Restored in Bortezomib Responder

多发性骨髓瘤中的血浆 Mir-92a 水平与 T 细胞衍生的 Mir-92a 相关并在硼替佐米应答器中恢复

• 发表时间: 2011
• 作者: Sei-ichiro Yoshizawa;Junko H. Ohyashiki;Michiyo Ohyashiki;Tomohiro Umezu;Kenshi Suzuki;Atsushi Inagaki;Shinsuke Iida;and Kazuma Ohyashiki
• 通讯作者: and Kazuma Ohyashiki